


Product Name : Sunvozertinib
Cat. No. : PC-38101
CAS No. : 2370013-49-1
Molecular Formula : C₂₉H₃₅ClFN₇O₃
Molecular Weight : 584.093
Target : EGFR
Solubility : 10 mM in DMSO



Biological Activity

DZD9008 (Sunvozertinib) is an oral, potent, irreversible, wild type-selective **EGFR** inhibitor against EGFR or HER2 Exon20ins and other mutations (IC₅₀=0.4-2.1 nM).

DZD9008 downregulates pEGFR with IC₅₀ ranging from 1 to 22 nM in a panel of tumor cell lines expressing EGFR L858R, Exon19del, L858R/T790M, various Exon20ins or uncommon mutations.

DZD9008 shows similar potency against pHER2 in tumor cells with HER2 Exon20ins mutation, with IC₅₀ of 7 nM.

DZD9008 is less potent in modulating pEGFR in tumor cells expressing wild type EGFR (IC₅₀>80 nM).

DZD9008 suppressed cell proliferation with GI₅₀ of 1 to 60 nM in tumor cells carrying EGFR L858R, Exon19del, L858R/T790M, various Exon20ins or uncommon mutations in cell proliferation assays.

DZD9008 exhibits tumor growth inhibition and regression in CDX and PDX models carrying EGFR Exon19del single mutation, L858R/T790M double mutations, and PDX models harboring G719S/L861Q or Exon20ins.

References

Yan Xu, et al. AACR Abstract 3081, **Cancer Res** (2019) 79 (13_Supplement): 3081.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com